An Open-Label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy and in Combination with Bortezomib and Dexamethasone in Japanese Relapsed Multiple Myeloma Patients, Trial ID 115960

An Open-Label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy and in Combination with Bortezomib and Dexamethasone in Japanese Relapsed Multiple Myeloma Patients, Trial ID 115960 | GSK